Endocrine Tumors of the Pancreas

Endocrinology and Metabolism Clinics of North America

Volumn 35, Issue 2, 2006, Pages 431-447

  Simon, Peter ^a   Spilcke Liss, Elisabeth ^a   Wallaschofski, Henri ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYINDOLEACETIC ACID; CALCITONIN; CHLOROZOTOCIN; CORTICOTROPIN; DACARBAZINE; DIAZOXIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIRUBICIN; FLUOROURACIL; GASTRIN; GLUCAGON; GLUCOCORTICOID; GROWTH HORMONE RELEASING FACTOR; LOMUSTINE; OCTREOTIDE; OMEPRAZOLE; PARATHYROID HORMONE RELATED PROTEIN; PHENYTOIN; PROTON PUMP INHIBITOR; RECOMBINANT ALPHA INTERFERON; SEROTONIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; THALIDOMIDE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VERAPAMIL;

AUTOPSY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; EDEMA; ENDOCRINE TUMOR; FAMILY HISTORY; GASTRINOMA; GLUCAGONOMA; HEALTH SURVEY; HIRSUTISM; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; IMAGE ANALYSIS; IMAGING SYSTEM; INFUSION; INHERITANCE; INSULINOMA; LIFE EXPECTANCY; LOW DRUG DOSE; NEPHROTOXICITY; NEUROFIBROMATOSIS; NEUROSECRETORY CELL; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW; SOMATOSTATINOMA; STOMACH ACID SECRETION; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; VIPOMA; VON HIPPEL LINDAU DISEASE;

DIAGNOSTIC IMAGING; DRUG THERAPY; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646058882     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2006.02.011     Document Type: Review

References (51)

1. Kaltsas G.A., Besser G.M., and Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25 (2004) 458-511
2. Rindi G., Villanacci V., Ubiali A., et al. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 1 (2001) 323-333
3. Solcia E., Kloppel G., and Sobin L.H. Histological typing of endocrine tumours. 2nd edition (2000), World Health Organization, Heidelberg
4. Rindi G., Villanacci V., and Ubiali A. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 62 Suppl 1 (2000) 19-26
5. Lack E.E., Lloyd R.V., Carney J.A., et al. Recommendations for reporting of extra-adrenal paragangliomas. Mod Pathol 16 (2003) 833-835
6. Kloppel G. Classification of neuroendocrine tumors. Verh Dtsch Ges Pathol 81 (1997) 111-117
7. Gumbs A.A., Moore P.S., Falconi M., et al. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol 81 (2002) 45-53
8. Wick M.R., and Graeme-Cook F.M. Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information. Am J Clin Pathol 115 (2001) S28-S45
9. Owen N.J., Sohaib S.A., Peppercorn P.D., et al. MRI of pancreatic neuroendocrine tumours. Br J Radiol 74 (2001) 968-973
10. Oberg K., and Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 (2005) 753-781
11. Service F.J., McMahon M.M., O'Brien P.C., et al. Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 66 (1991) 711-719
12. Roy P.K., Venzon D.J., Shojamanesh H., et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 79 (2000) 379-411
13. Soga J., and Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 17 (1998) 389-400
14. Soga J., and Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocarcrinomas. J Exp Clin Cancer Res 18 (1999) 13-22
15. Chastain M.A. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 321 (2001) 306-320
16. Mao C., el Attar A., Domenico D.R., et al. Carcinoid tumors of the pancreas: status report based on two cases and review of the world's literature. Int J Pancreatol 23 (1998) 153-164
17. Venkatesh S., Ordonez N.G., Ajani J., et al. Islet cell carcinoma of the pancreas: a study of 98 patients. Cancer 65 (1990) 354-357
18. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 62 Suppl 1 (2000) 51-58
19. Zhuang Z., Vortmeyer A.O., Pack S., et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57 (1997) 4682-4686
20. Plockinger U., and Wiedemann B. Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology 80 Suppl 1 (2004) 35-38
21. Weber H.C., Venzon D.J., Lin J.T., et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108 (1995) 1637-1649
22. Wang E.H., Ebrahimi S.A., Wu A.Y., et al. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 58 (1998) 4417-4420
23. Akerstrom G., Hessman O., Hellman P., et al. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol 19 (2005) 819-830
24. Kaltsas G., Rockall A., Papadogias D., et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 151 (2004) 15-27
25. Kaltsas G.A., Mukherjee J.J., and Grossman A.B. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol 12 Suppl 2 (2001) S47-S50
26. Rosch T., Lightdale C.J., Botet J.F., et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326 (1992) 1721-1726
27. Glover J.R., Shorvon P.J., and Lees W.R. Endoscopic ultrasound for localisation of islet cell tumours. Gut 33 (1992) 108-110
28. Anderson M.A., Carpenter S., Thompson N.W., et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 95 (2000) 2271-2277
29. Legmann P., Vignaux O., Dousset B., et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 170 (1998) 1315-1322
30. Semelka R.C., Cumming M.J., Shoenut J.P., et al. Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology 186 (1993) 799-802
31. Arnold R., and Frank M. Control of growth in neuroendocrine gastro-enteropancreatic tumours. Digestion 57 Suppl 1 (1996) 69-71
32. Arnold R., and Hiddemann W. Therapy of metastatic endocrine tumors of the gastrointestinal tract. Dtsch Med Wochenschr 121 (1996) 1346-1347
33. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 (1999) 635-644
34. Arnold R., and Frank M. Gastrointestinal endocrine tumours: medical management. Baillieres Clin Gastroenterol 10 (1996) 737-759
35. Arnold R., Simon B., and Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62 Suppl 1 (2000) 84-91
36. Aparicio T., Ducreux M., Baudin E., et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37 (2001) 1014-1019
37. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 Suppl 1 (2000) 92-97
38. Jacobsen M.B., Hanssen L.E., Kolmannskog F., et al. Interferon-α 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian Carcinoid Study. Scand J Gastroenterol 30 (1995) 789-796
39. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 10 (1998) 58-65
40. Oberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 (2004) 966-973
41. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
42. Eriksson B., and Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32 (1993) 203-208
43. Moertel C.G., Hanley J.A., and Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303 (1980) 1189-1194
44. Broder L.E., and Carter S.K. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79 (1973) 108-118
45. Bukowski R.M., Tangen C., Lee R., et al. 1992 Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. J Clin Oncol 10 (1992) 1914-1918
46. Bajetta E., Rimassa L., Carnaghi C., et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83 (1998) 372-378
47. Rivera E., and Ajani J.A. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21 (1998) 36-38
48. Cheng P.N., and Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 (1999) 944-948
49. Kaltsas G.A., Mukherjee J.J., Isidori A., et al. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf) 57 (2002) 169-183
50. Troncone L., and Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 43 (1999) 344-355
51. Nguyen C., Faraggi M., Giraudet A.L., et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (2004) 1660-1668